Amgen: Phase 2 results for GLP-1-GIP weight loss drug
Nov 28, 2024 · A number of different drugs, such as Novo Nordisk’s Ozempic, target either the GLP-1 or GIP receptor. Like Eli Lilly’s Mounjaro/Zepbound (tirzepatide), MariTide targets both receptors simultaneously, thereby having a stronger weight loss effect, as suggested by preclinical studies.Next to the dual mechanism of action, the antibody-peptide combination also gives the drug a longer half-life ...
Aditum Bio and Leads Biolabs join forces to fight autoimmune …
Nov 7, 2024 · The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new company that will develop a potentially first-in-class tri-specific T cell engager for the treatment of difficult-to-treat autoimmune diseases.
Astellas licenses AviadoBio’s dementia gene therapy candidate
Oct 10, 2024 · “This strategic collaboration will combine our promising gene therapy candidate for FTD-GRN and delivery expertise with Astellas’ global capabilities in development and commercialization of gene therapies.
AbbVie acquires Aliada Therapeutics in $1.4bn deal
Oct 30, 2024 · Based in Boston, US, Aliada Therapeutics was founded in 2021 by Johnson & Johnson together with venture capital firm RA Capital Management. The company’s MODEL platform was originally created at Johnson & Johnson and licensed to Aliada when it was created.
BMS achieves FDA approval for schizophrenia drug Cobenfy
Oct 1, 2024 · Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity value that completed earlier this year. The deal has paid off as Karuna’s lead asset was approved last week by the US FDA.. Cobenfy is a combination of xanomeline, which acts on the muscarinic receptor system by activating it and trospium, which blocks the muscarinic ...
Toxoplasma parasite engineered to deliver treatments to brain
Aug 21, 2024 · A team of scientists from the universities of Glasgow and Tel Aviv has developed a groundbreaking method to transform the brain parasite Toxoplasma gondii into a potential vehicle for delivering therapeutic treatments directly to brain cells.
The top 5 CDMOs developing advanced therapies
Jul 18, 2024 · Headquarters: Somerset, New Jersey, US. Founded: 2007. Catalent was set up when Blackstone acquired the pharmaceutical and services assets from Cardinal Health and rebranded them under their current name.. Catalent handles the production and supply of therapeutic products across the range of small molecules and biologics.
Adcentrx gets FDA clearance for phase 1 trial of ADC for tumors
Oct 22, 2024 · ADCs are becoming increasingly popular. This latest IND application clearance reflects the rising popularity of ADCs. Recent ADC news included a $1 billion deal between the Danish company Adcendo and Chinese Multitude Therapeutics, as well as a $114 million series A by UK startup Myricx Bio to advance its ADC pipeline.. In fact, a new study by the U.S. company BCC Research has revealed that ...
Alto Neuroscience’s depression drug trial fails at phase 2
Oct 24, 2024 · Alto Neuroscience has a focus on developing new neuropsychiatric medications. The company is using a combination of artificial intelligence (AI), brain activity and biomarker analysis to select new and better targeted potential drug candidates to advance to clinical trials.
Spyre Therapeutics: Phase 1 trials for extended half-life IBD therapy
Dec 3, 2024 · The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 trials testing its first-generation anti-TL1A antibodies, SPY002-091 and SPY002-072, for the treatment of inflammatory bowel disease (IBD).